Compare NEOS S&P 500 High Income ETF (SPYI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NEOS S&P 500 High Income ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? NEOS S&P 500 High Income ETF trades at $53.59 (market cap $12.59B), while Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B). The key difference: NEOS S&P 500 High Income ETF is the larger of the two by market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NEOS S&P 500 High Income ETF for 59 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SPYI | SYRE | |
|---|---|---|
Market Cap | $12.59B | $7.35B |
Volume | 3,517,447 | 1,624,631 |
Sector | Income / Options Overlay | Health |
52-Week High | $54.42 | $108.92 |
52-Week Low | $47.98 | $22.18 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPYI trades at $54.11 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. Recent news highlights SPYI's role in income-focused portfolios while raising concerns about principal erosion from covered call strategies. The ETF's dividend payments remain consistent with recent distributions around $0.53-0.54 per share.
The outlook for SPYI balances high income generation against capital preservation risks. While the covered call strategy provides attractive yields, investors face potential principal erosion during market rallies. Recent analyst coverage suggests a cautious approach given the trade-offs between income stability and growth limitations inherent in the fund's strategy.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
